Browse the evidence

GLP-1-agonists significantly reduce the risk of cardiovascular endpoints in patients with overweight or obesity without diabetes, with a Number Needed to Treat (NNT) of 44.

GLP-1-agonists may be considered for reducing cardiovascular risk in non-diabetic patients with obesity.

Incretin drug therapy can produce significant weight loss in properly selected individuals.

Clinicians should consider incretin therapy for weight loss in appropriately selected patients.

Bariatric surgery is the most effective treatment for obesity, yielding sustainable weight loss of about 20-30%.

Bariatric surgery should be considered for patients with obesity seeking significant weight loss.

GLP-1 receptor agonist semaglutide 2.4 mg and dual GLP-1 and GIP agonist tirzepatide have raised the bar for weight loss efficacy in obesity pharmacotherapies.

Clinicians should consider GLP-1 and GIP agonists as effective options for obesity treatment.

Combinations of GLP-1 RA, GIP, and glucagon RA (retatrutide) have shown weight loss efficacy approaching that of bariatric surgery.

Combination therapies may offer significant weight loss benefits similar to surgical options.

Second-generation drugs for obesity treatment can achieve weight loss of 15-25%, comparable to bariatric surgery.

Healthcare professionals can consider second-generation drugs as effective options for weight management in obese patients.

GLP-1 receptor agonists can achieve weight loss of 15-17% with a good safety profile.

GLP-1 receptor agonists are a viable treatment option for weight loss in obese patients.

Tirzepatide can achieve weight loss of up to 22.5% at the highest doses.

Tirzepatide represents a potent option for significant weight loss in obese patients.

Once-weekly GLP-1RA therapy can produce substantial weight loss over prolonged treatment (up to 23% at 72 weeks), alongside improvements in metabolic outcomes and reduced cardiometabolic risk.

GLP-1RA therapies can be effective for significant weight loss and improving metabolic health in obese patients.

Inkretin-basierte Medikamente (GLP-1- und GIP/GLP-1-Rezeptoragonisten) und SGLT-2-Inhibitoren (SGLT2i) ermöglichen eine bislang nicht erreichte Gewichtsreduktion und reduzieren nachweislich kardiovaskuläre Ereignisse (MACE).

Practitioners should consider these medications as effective options for weight management and cardiovascular risk reduction.

Die Kombination von GLP-1-Rezeptoragonisten und SGLT2i zeigt additive Vorteile und wird leitliniengerecht bei Typ-2-Diabetes mit hohem Risiko empfohlen.

Healthcare providers should consider this combination therapy for high-risk type 2 diabetes patients.

Advanced pharmacotherapy with GLP-1 receptor agonists can achieve 15%–20% weight loss.

Clinicians can consider GLP-1 receptor agonists as an effective pharmacotherapy option for weight loss.

Recent antiobesity drugs have shown weight loss effects of 12%–17% and can resolve NASH in some patients.

Consider the use of antiobesity medications as part of a comprehensive treatment plan for NASH.

Tirzepatide has demonstrated superior efficacy in promoting weight loss and maintaining a healthy body weight compared to traditional incretin therapies.

Tirzepatide may be a more effective option for weight management in patients with obesity.

Dual agonists improve glycemic control and promote substantial weight loss.

Practitioners can consider dual agonists as effective options for improving glycemic control and aiding weight loss in patients with metabolic diseases.

Phase 3 clinical trials showed superior efficacy of tirzepatide compared to existing pharmacotherapies, reaching body weight reductions of approximately 22.5% and hemoglobin A1c (HbA1c) reductions of up to 2.4 percentage points.

Tirzepatide may be a more effective treatment option for weight loss and glycemic control in patients with obesity and T2DM.

Phase 2 trials of retatrutide revealed weight reductions approaching 24.2% over 48 weeks.

Retatrutide may offer substantial weight loss benefits for individuals with obesity over a 48-week period.

Antiobesity drugs can lead to a mean total body weight loss of 10% to nearly 20% at high dosages.

Antiobesity medications can be effective for weight loss in specific patient populations.

Tirzepatide significantly improved physical function compared with placebo, with a mean difference of 10.10 points in the IWQOL-Lite-CT physical function subscale.

Practitioners can consider tirzepatide as an effective treatment to enhance physical function in adults with overweight or obesity.

Once-monthly maridebart has produced clinically meaningful weight loss of approximately 12–16% in adults without diabetes and 8–12% in those with type 2 diabetes.

Practitioners can expect significant weight loss outcomes with once-monthly maridebart in their patients.

GLP-1 receptor agonists (GLP-1 RAs) are used to treat type 2 diabetes and obesity due to benefits in glycemic control, weight loss, and cardiovascular risk reduction.

Practitioners should consider GLP-1 RAs for managing type 2 diabetes and obesity.

Both tirzepatide and semaglutide significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels in solid-organ transplant recipients.

Both medications can be considered effective options for managing diabetes in transplant patients.

Participants without type 2 diabetes (T2D) achieved significantly greater weight loss than those with T2D, with a median weight loss of 11.21% vs 5.48%, P < 0.001.

Practitioners should consider diabetes status when setting weight loss expectations for patients.

Tirzepatide was associated with greater weight loss compared with semaglutide, with a median weight loss of 8.60% vs 5.62%, P = 0.023.

Clinicians may prefer tirzepatide over semaglutide for better weight loss outcomes.